{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:17:39Z","timestamp":1793945859645,"version":"4.8.0"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009192","name":"Alberta Innovates","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009192","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.metabol.2024.155818","type":"journal-article","created":{"date-parts":[[2024,2,16]],"date-time":"2024-02-16T21:16:47Z","timestamp":1708118207000},"page":"155818","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation"],"prefix":"10.1016","volume":"154","author":[{"given":"Simran","family":"Pherwani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Connolly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qutuba G.","family":"Karwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim L.","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cory S.","family":"Wagg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jody","family":"Levasseur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heidi","family":"Silver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason R.B.","family":"Dyck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Lopaschuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.metabol.2024.155818_bb0005","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"issue":"4","key":"10.1016\/j.metabol.2024.155818_bb0010","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/0002-9343(54)90365-4","article-title":"Metabolism of the human heart: II. Studies on fat, ketone and amino acid metabolism","volume":"16","author":"Bing","year":"1954","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.metabol.2024.155818_bb0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1152\/physrev.00015.2009","article-title":"Myocardial fatty acid metabolism in health and disease","volume":"90","author":"Lopaschuk","year":"2010","journal-title":"Physiol Rev"},{"issue":"2","key":"10.1016\/j.metabol.2024.155818_bb0020","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0146-2806(94)90008-6","article-title":"Energy metabolism of the heart: from basic concepts to clinical applications applications","volume":"19","author":"Taegtmeyer","year":"1994","journal-title":"Curr Probl Cardiol"},{"issue":"11","key":"10.1016\/j.metabol.2024.155818_bb0025","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1056\/NEJMra063052","article-title":"The failing heart\u2014an engine out of fuel","volume":"356","author":"Neubauer","year":"2007","journal-title":"New England Journal of Medicine."},{"issue":"5","key":"10.1016\/j.metabol.2024.155818_bb0030","first-page":"1039","article-title":"Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circulation","volume":"6","author":"Zhang","year":"2013","journal-title":"Heart Failure."},{"issue":"4","key":"10.1016\/j.metabol.2024.155818_bb0035","first-page":"493","article-title":"Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circulation","volume":"5","author":"Mori","year":"2012","journal-title":"Heart Failure."},{"issue":"25","key":"10.1016\/j.metabol.2024.155818_bb0040","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.2174\/1381612821666150710150445","article-title":"Myocardial energy substrate metabolism in heart failure: from pathways to therapeutic targets","volume":"21","author":"Fukushima","year":"2015","journal-title":"Curr Pharm Des"},{"issue":"11","key":"10.1016\/j.metabol.2024.155818_bb0045","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1093\/cvr\/cvz045","article-title":"Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency","volume":"115","author":"Ho","year":"2019","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.metabol.2024.155818_bb0050","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0735-1097(96)00214-8","article-title":"Blood ketone bodies in congestive heart failure","volume":"28","author":"Lommi","year":"1996","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.metabol.2024.155818_bb0055","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/CIRCULATIONAHA.115.017545","article-title":"Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure","volume":"133","author":"Bedi","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.metabol.2024.155818_bb0060","series-title":"Increased cardiac uptake of ketone bodies and free fatty acids in human heart failure and hypertrophic left ventricular remodeling","first-page":"e004953","volume":"vol. 11(12)","author":"Voros","year":"2018"},{"issue":"8","key":"10.1016\/j.metabol.2024.155818_bb0065","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1161\/CIRCULATIONAHA.115.017355","article-title":"The failing heart relies on ketone bodies as a fuel","volume":"133","author":"Aubert","year":"2016","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.metabol.2024.155818_bb0070","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.124079","article-title":"The failing heart utilizes 3-hydroxybutyrate as a metabolic stress defense","volume":"4","author":"Horton","year":"2019","journal-title":"JCI insight"},{"key":"10.1016\/j.metabol.2024.155818_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2020.154452","article-title":"Myocardial ketone body utilization in patients with heart failure: the impact of oral ketone ester","volume":"115","author":"Monzo","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155818_bb0080","article-title":"Ketone ester supplementation suppresses cardiac inflammation and improves cardiac energetics in a swine model of acute myocardial infarction","volume":"155608","author":"Yurista","year":"2023","journal-title":"Metabolism"},{"issue":"11","key":"10.1016\/j.metabol.2024.155818_bb0085","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.metabol.2014.08.001","article-title":"Using positron emission tomography to study human ketone body metabolism: a review","volume":"63","author":"Bouteldja","year":"2014","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.metabol.2024.155818_bb0090","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.molmet.2014.07.010","article-title":"Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling","volume":"3","author":"Schugar","year":"2014","journal-title":"Molecular metabolism"},{"issue":"18","key":"10.1016\/j.metabol.2024.155818_bb0095","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1161\/CIRCULATIONAHA.118.036459","article-title":"Cardiovascular effects of treatment with the ketone body 3-hydroxybutyrate in chronic heart failure patients","volume":"139","author":"Nielsen","year":"2019","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.metabol.2024.155818_bb0100","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/dc16-0542","article-title":"Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study?","volume":"39","author":"Mudaliar","year":"2016","journal-title":"A unifying hypothesis Diabetes care"},{"issue":"7","key":"10.1016\/j.metabol.2024.155818_bb0105","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG OUTCOME trial: a \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.metabol.2024.155818_bb0110","first-page":"575","article-title":"Empagliflozin increases cardiac energy production in diabetes: novel translational insights into the heart failure benefits of SGLT2 inhibitors. JACC: basic to translational","volume":"3","author":"Verma","year":"2018","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.metabol.2024.155818_bb0115","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England Journal of Medicine."},{"issue":"5","key":"10.1016\/j.metabol.2024.155818_bb0120","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium\u2013glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"6","key":"10.1016\/j.metabol.2024.155818_bb0125","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/dom.12881","article-title":"Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients","volume":"19","author":"Al Jobori","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.metabol.2024.155818_bb0130","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1128\/MCB.06470-11","article-title":"Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunction","volume":"32","author":"Kienesberger","year":"2012","journal-title":"Mol Cell Biol"},{"issue":"2","key":"10.1016\/j.metabol.2024.155818_bb0135","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1152\/physiolgenomics.00026.2004","article-title":"Comprehensive transthoracic cardiac imaging in mice using ultrasound biomicroscopy with anatomical confirmation by magnetic resonance imaging","volume":"18","author":"Zhou","year":"2004","journal-title":"Physiol Genomics"},{"key":"10.1016\/j.metabol.2024.155818_bb0140","doi-asserted-by":"crossref","unstructured":"OLSON RE, SCHWARTZ WB. Myocardial metabolism in congestive heart failure. Medicine 1951;30(1):21\u201342.","DOI":"10.1097\/00005792-195102000-00002"},{"issue":"11","key":"10.1016\/j.metabol.2024.155818_bb0145","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1161\/01.CIR.94.11.2837","article-title":"Fatty acid oxidation enzyme gene expression is downregulated in the failing heart","volume":"94","author":"Sack","year":"1996","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.metabol.2024.155818_bb0150","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1093\/cvr\/cvp414","article-title":"Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload","volume":"86","author":"Doenst","year":"2010","journal-title":"Cardiovasc Res"},{"issue":"6514","key":"10.1016\/j.metabol.2024.155818_bb0155","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1126\/science.abc8861","article-title":"Comprehensive quantification of fuel use by the failing and nonfailing human heart","volume":"370","author":"Murashige","year":"2020","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.metabol.2024.155818_bb0160","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0008-6363(01)00393-5","article-title":"Postinfarction heart failure in rats is associated with upregulation of GLUT-1 and downregulation of genes of fatty acid metabolism","volume":"52","author":"Rosenblatt-Velin","year":"2001","journal-title":"Cardiovasc Res"},{"issue":"3","key":"10.1016\/j.metabol.2024.155818_bb0165","first-page":"420","article-title":"Analysis of metabolic remodeling in compensated left ventricular hypertrophy and heart failure. Circulation","volume":"3","author":"Kato","year":"2010","journal-title":"Heart Failure"},{"issue":"2","key":"10.1016\/j.metabol.2024.155818_bb0170","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0735-1097(02)01967-8","article-title":"Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy","volume":"40","author":"D\u00e1vila-Rom\u00e1n","year":"2002","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"10.1016\/j.metabol.2024.155818_bb0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0007533","article-title":"Substrate utilization by the failing human heart by direct quantification using arterio-venous blood sampling","volume":"4","author":"Funada","year":"2009","journal-title":"PloS One"},{"issue":"3","key":"10.1016\/j.metabol.2024.155818_bb0180","first-page":"266","article-title":"Mechanical unloading promotes myocardial energy recovery in human heart failure. Circulation: cardiovascular","volume":"7","author":"Gupte","year":"2014","journal-title":"Genetics"},{"issue":"4","key":"10.1016\/j.metabol.2024.155818_bb0185","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/cvr\/cvs424","article-title":"Pressure-overload-induced heart failure induces a selective reduction in glucose oxidation at physiological afterload","volume":"97","author":"Zhabyeyev","year":"2013","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.metabol.2024.155818_bb0190","series-title":"Cardiac-specific Bdh1 overexpression ameliorates oxidative stress and cardiac remodeling in pressure overload\u2013induced heart failure","first-page":"e004417","volume":"vol. 10(12)","author":"Uchihashi","year":"2017"},{"key":"10.1016\/j.metabol.2024.155818_bb0195","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3389\/fcvm.2018.00068","article-title":"Loss of metabolic flexibility in the failing heart","volume":"5","author":"Karwi","year":"2018","journal-title":"Frontiers in cardiovascular medicine"},{"issue":"12","key":"10.1016\/j.metabol.2024.155818_bb0200","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1016\/j.metabol.2024.155818_bb0205","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"Basic to Translational Science"},{"issue":"22","key":"10.1016\/j.metabol.2024.155818_bb0210","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"10.1016\/j.metabol.2024.155818_bb0215","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004007","article-title":"Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients","volume":"6","author":"Mazidi","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.metabol.2024.155818_bb0220","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium\u2013glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.metabol.2024.155818_bb0225","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1111\/dom.13488","article-title":"Increases in circulating levels of ketone bodies and cardiovascular protection with SGLT2 inhibitors: is low-grade inflammation the neglected component?","volume":"20","author":"Prattichizzo","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.metabol.2024.155818_bb0230","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radical Biology and Medicine"},{"key":"10.1016\/j.metabol.2024.155818_bb0235","series-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","first-page":"e006277","volume":"vol. 13(1)","author":"Byrne","year":"2020"},{"issue":"4","key":"10.1016\/j.metabol.2024.155818_bb0240","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1093\/cvr\/cvaa143","article-title":"Ketones can become the major fuel source for the heart but do not increase cardiac efficiency","volume":"117","author":"Ho","year":"2021","journal-title":"Cardiovasc Res"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524000441?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524000441?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:34:33Z","timestamp":1758429273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524000441"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":48,"alternative-id":["S0026049524000441"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155818","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155818","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155818"}}